Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group

Smita Bhatia*, Mark D. Krailo, Zhengjia Chen, Laura Burden, Frederic B. Askin, Paul S. Dickman, Holcombe E. Grier, Michael P. Link, Paul A. Meyers, Elizabeth J. Perlman, Aaron R. Rausen, Leslie L. Robison, Teresa J. Vietti, James S. Miser

*Corresponding author for this work

Research output: Contribution to journalArticle

90 Scopus citations

Abstract

This study describes the magnitude of risk of therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) in 578 individuals diagnosed with Ewing sarcoma and enrolled on Children's Oncology Group therapeutic protocol, INT-0091. Between 1988 and 1992, patients with or without metastatic disease were randomized to receive doxorubicin, vincristine, cyclophosphamide, and dactinomycin (regimen A) or these 4 drugs alternating with etoposide and ifosfamide (regimen B). Between 1992 and 1994, patients with metastatic disease were nonrandomly assigned to receive high-intensity therapy (regimen C: regimen B therapy with higher doses of doxorubicin, cyclophosphamide, and ifosfamide). Median age at diagnosis of Ewing sarcoma was 12 years, and median length of followup, 8 years. Eleven patients developed t-MDS/AML, resulting in a cumulative incidence of 2% at 5 years. While patients treated on regimens A and B were at a low risk for development of t-MDS/AML (cumulative incidence: 0.4% and 0.9% at 5 years, respectively), patients treated on regimen C were at a 16-fold increased risk of developing t-MDS/AML (cumulative incidence: 11% at 5 years), when compared with those treated on regimen A. Increasing exposure to ifosfamide from 90 to 140 g/m2, cyclophosphamide from 9.6 to 17.6 g/m2, and doxorubicin from 375 to 450 mg/m2 increased the risk of t-MDS/AML significantly.

Original languageEnglish (US)
Pages (from-to)46-51
Number of pages6
JournalBlood
Volume109
Issue number1
DOIs
StatePublished - Jan 1 2007

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group'. Together they form a unique fingerprint.

  • Cite this

    Bhatia, S., Krailo, M. D., Chen, Z., Burden, L., Askin, F. B., Dickman, P. S., Grier, H. E., Link, M. P., Meyers, P. A., Perlman, E. J., Rausen, A. R., Robison, L. L., Vietti, T. J., & Miser, J. S. (2007). Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood, 109(1), 46-51. https://doi.org/10.1182/blood-2006-01-023101